Sponsor: 
Pfizer Australia
Administration route: 
Intramuscular injection
Vaccine group: 
Monovalent meningococcal C vaccine

Registered for use in children aged ≥8 weeks and in adults.

MenC — monovalent meningococcal serogroup C–tetanus toxoid conjugate vaccine

Each 0.5 mL monodose pre-filled syringe contains:

  • 10 µg Neisseria meningitidis serogroup C
  • 10–20 µg tetanus toxoid protein

Adsorbed onto 1.4 mg aluminium hydroxide.

The product information and consumer medicine information for NeisVac-C have more details.

Audience: 
Infants and children
Previous

Mérieux Inactivated Rabies Vaccine

Next

Nimenrix

Page history

Last updated: 
4 June 2018
Last reviewed: 
4 June 2018